NAVB logo

Navidea Biopharmaceuticals (NAVB) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 November 1992

Indexes:

Not included

Description:

Navidea Biopharmaceuticals focuses on developing innovative imaging agents and therapies for diagnosing and treating diseases, particularly in oncology and autoimmune disorders. The company aims to improve patient outcomes through advanced medical technologies and targeted treatments.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 21, 2024

Recent annual earnings:

Mar 21, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 26, 2019

Analyst ratings

Recent major analysts updates

No data about analysts updates

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
businesswire.com20 June 2024

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii.

Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
InvestorPlace31 July 2023

Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE American LLC sent the company a notice about its failure to comply with listing standards.

Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Market Watch30 June 2023

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.

FAQ

  • What is the primary business of Navidea Biopharmaceuticals?
  • What is the ticker symbol for Navidea Biopharmaceuticals?
  • Does Navidea Biopharmaceuticals pay dividends?
  • What sector is Navidea Biopharmaceuticals in?
  • What industry is Navidea Biopharmaceuticals in?
  • What country is Navidea Biopharmaceuticals based in?
  • When did Navidea Biopharmaceuticals go public?
  • Is Navidea Biopharmaceuticals in the S&P 500?
  • Is Navidea Biopharmaceuticals in the NASDAQ 100?
  • Is Navidea Biopharmaceuticals in the Dow Jones?
  • When was Navidea Biopharmaceuticals's last earnings report?
  • When does Navidea Biopharmaceuticals report earnings?
  • Should I buy Navidea Biopharmaceuticals stock now?

What is the primary business of Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals focuses on developing innovative imaging agents and therapies for diagnosing and treating diseases, particularly in oncology and autoimmune disorders. The company aims to improve patient outcomes through advanced medical technologies and targeted treatments.

What is the ticker symbol for Navidea Biopharmaceuticals?

The ticker symbol for Navidea Biopharmaceuticals is NYSE American:NAVB

Does Navidea Biopharmaceuticals pay dividends?

No, Navidea Biopharmaceuticals does not pay dividends

What sector is Navidea Biopharmaceuticals in?

Navidea Biopharmaceuticals is in the Healthcare sector

What industry is Navidea Biopharmaceuticals in?

Navidea Biopharmaceuticals is in the Biotechnology industry

What country is Navidea Biopharmaceuticals based in?

Navidea Biopharmaceuticals is headquartered in United States

When did Navidea Biopharmaceuticals go public?

Navidea Biopharmaceuticals's initial public offering (IPO) was on 10 November 1992

Is Navidea Biopharmaceuticals in the S&P 500?

No, Navidea Biopharmaceuticals is not included in the S&P 500 index

Is Navidea Biopharmaceuticals in the NASDAQ 100?

No, Navidea Biopharmaceuticals is not included in the NASDAQ 100 index

Is Navidea Biopharmaceuticals in the Dow Jones?

No, Navidea Biopharmaceuticals is not included in the Dow Jones index

When was Navidea Biopharmaceuticals's last earnings report?

Navidea Biopharmaceuticals's most recent earnings report was on 21 November 2024

When does Navidea Biopharmaceuticals report earnings?

The date for Navidea Biopharmaceuticals's next earnings report has not been announced yet

Should I buy Navidea Biopharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions